Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 709,477
  • Shares Outstanding, K 59,470
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -72,550 K
  • 60-Month Beta 1.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.34
  • Number of Estimates 8
  • High Estimate -0.30
  • Low Estimate -0.38
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.90 +9.45%
on 02/27/19
14.00 -14.79%
on 03/05/19
+0.59 (+5.20%)
since 02/22/19
3-Month
6.31 +89.06%
on 12/24/18
14.00 -14.79%
on 03/05/19
+5.39 (+82.42%)
since 12/21/18
52-Week
6.31 +89.06%
on 12/24/18
15.00 -20.47%
on 06/20/18
-0.83 (-6.50%)
since 03/22/18

Most Recent Stories

More News
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 11.93 (-7.66%)
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 11.93 (-7.66%)
CymaBay Announces Pricing of Public Offering of Common Stock

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 11.93 (-7.66%)
CymaBay Announces Proposed Public Offering of Common Stock

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 11.93 (-7.66%)
CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial...

CBAY : 11.93 (-7.66%)
Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Apple Inc. (NASDAQ:AAPL), United...

UAL : 79.63 (-1.69%)
AAPL : 191.05 (-2.07%)
GVA : 43.11 (-6.04%)
CBAY : 11.93 (-7.66%)
IMGN : 2.41 (-6.23%)
FTK : 3.15 (-2.78%)
CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it...

CBAY : 11.93 (-7.66%)
CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management...

CBAY : 11.93 (-7.66%)
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

-- Over 80% of subjects had baseline F2 or F3 stage fibrosis

CBAY : 11.93 (-7.66%)
CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage...

CBAY : 11.93 (-7.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CBAY with:

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 13.14
1st Resistance Point 12.53
Last Price 11.93
1st Support Level 11.62
2nd Support Level 11.32

See More

52-Week High 15.00
Last Price 11.93
Fibonacci 61.8% 11.68
Fibonacci 50% 10.65
Fibonacci 38.2% 9.63
52-Week Low 6.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar